Emergence of quinolone resistance and cephalosporin MIC creep in Neisseria gonorrhoeae isolates from a cohort of young men in Kisumu, Kenya, 2002 to 2009

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 8, 2011, Pages 3882-3888

  Mehta, Supriya D ^a   Maclean, Ian ^b   Ndinya Achola, Jeckoniah O ^c   Moses, Stephen ^b   Martin, Irene ^d   Ronald, Allan ^b   Agunda, Lawrence ^e   Murugu, Ruth ^e   Bailey, Robert C ^a   Melendez, Johan ^f   Zenilman, Jonathan M ^f  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF NAIROBI   (Kenya)

^d Public Health Agency of Canada   (Canada)

^e UNIM Project   (Kenya)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; METRONIDAZOLE; NORFLOXACIN; PENICILLIN G; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPECTINOMYCIN; TETRACYCLINE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL MUTATION; BACTERIUM CULTURE; BACTERIUM ISOLATE; CIRCUMCISION; FEMALE; GONORRHEA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; KENYA; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEISSERIA GONORRHOEAE; NONHUMAN; PENICILLIN RESISTANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; TRICHOMONIASIS; URETHRA; URETHRITIS;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CIRCUMCISION, MALE; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GONORRHEA; HUMANS; KENYA; MALE; NEISSERIA GONORRHOEAE; PLASMIDS; POLYMERASE CHAIN REACTION; QUINOLONES; URETHRITIS; YOUNG ADULT;

EID: 79960291264     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00155-11     Document Type: Article

References (48)

1. Ameyama, S., et al. 2002. Mosaic-like structure of penicillin-binding protein 2 gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob. Agents Chemother. 46:3744-3749.
2. Australian Gonococcal Surveillance Programme. 2010. Annual report of the Australian Gonococcal Surveillance Programme, 2009. Commun. Dis. Intell. 34:89-95. http://www.who.int/drugresistance/WHO-Global-Strategy-English.pdf. Accessed 17 November 17 2010.
3. Bailey, R. C., et al. 2007. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369:643-656. (Pubitemid 46281312)
4. Bala, M., and S. Sood. 2010. Cephalosporin resistance in Neisseria gonorrhoeae. J. Glob. Infect. Dis. 2:284-290.
5. Bowie, W., A. R. Ronald, W. Krywulak, C. Y. Cates, and P. Boutros. 1974. Gentamicin in the treatment of gonorrhoea in females. Br. J. Vener. Dis. 50:208-211.
6. Centers for Disease Control and Prevention. 1993. 1993 Sexually transmitted diseases treatment guidelines. MMWR Recommend. Rep. 42(RR-14):1-102.
7. Centers for Disease Control and Prevention. 2004. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men-United States, 2003, and revised recommendations for gonorrhea treatment, 2004. MMWR Morb. Mortal. Wkly. Rep. 53:335-338.
8. Centers for Disease Control and Prevention. 2006. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recommend. Rep. 55(RR-11):44.
9. Centers for Disease Control and Prevention. 2007. Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb. Mortal. Wkly. Rep. 56:332-336.
10. Chisholm, S. A., et al. 2010. Expanded cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J. Antimicrob. Chemother. 65:2141-2148.
11. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing: nineteenth informational supplement. M100-S20, vol. 30, no. 1. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Cole, M. J., et al. 2010. European surveillance of antimicrobial resistance in Neisseria gonorrhoeae. Sex. Transm. Infect. 86:427-432.
13. De Jongh, M., Y. Dangor, A. Adam, and A. A. Hoosen. 2007. Gonococcal resistance: evolving from penicillin, tetracycline to the quinolones in South Africa - implications for treatment guidelines. Int. J. STD AIDS 18:697-699.
14. Ehret, J. M., L. J. Nims, and F. N. Judson. 1996. A clinical isolate of Neisseria gonorrhoeae with in vitro resistance to erythromycin and decreased susceptibility to azithromycin. Sex. Transm. Dis. 23:270-272.
15. Farhi, D., et al. 2007. Increasing rates of quinolone-resistant Neisseria gonorrhoeae in Paris, France. J. Eur. Acad. Dermatol. Venereol. 21:818-821.
16. Fudyk, T. C., et al. 1999. Genetic diversity and mosaicism at the por locus of Neisseria gonorrhoeae. J. Bacteriol. 181:5591-5599. (Pubitemid 29437128)
17. Giles, J. A., et al. 2004. Quinolone resistance-determining region mutations and por type of Neisseria gonorrhoeae isolates: resistance surveillance and typing by molecular methodologies. J. Infect. Dis. 189:2085-2093.
18. Golparian, D., B. Hellmark, H. Fredlund, and M. Unemo. 2010. Emergence, spread and characteristics of Neisseria gonorrhoeae isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden. Sex. Transm. Infect. 86:454-460.
19. Guyot, A., B. Jarrett, L. Sanvee, and D. Dore. 1998. Antimicrobial resistance of Neisseria gonorrhoeae in Liberia. Trans. R. Soc. Trop. Med. Hyg. 92:670-674.
20. Hira, S. K., et al. 1985. Efficacy of gentamicin and kanamycin in the treatment of uncomplicated gonococcal urethritis in Zambia. Sex. Transm. Dis. 12:52-54.
21. Huang, C. T., et al. 2010. Characteristics and dissemination of mosaic penicillin-binding protein 2-harboring multidrug-resistant Neisseria gonorrhoeae isolates with reduced cephalosporin susceptibility in northern Taiwan. Antimicrob. Agents Chemother. 54:4893-4895.
22. Ison, C. A., K. M. Bindayna, N. Woodford, M. J. Gill, and C. S. Easmon. 1990. Penicillin and cephalosporin resistance in gonococci. Genitourin. Med. 66:351-356.
23. Jain, S. K., M. G. Kulkarni, and D. D. Banker. 1994. Antibiotic susceptibility pattern of gonococcal isolates. Indian J. Med. Sci. 48:233-236.
24. Joesoef, M. R., et al. 1994. Antimicrobial susceptibilities of Neisseria gonorrhoeae strains isolated in Surabaya, Indonesia. Antimicrob. Agents Chemother. 38:2530-2533.
25. Lewis, D. A., et al. 2008. Escalation in the relative prevalence of ciprofloxacin-resistant gonorrhoeae among men with urethral discharge in two South African cities: association with HIV seropositivity. Sex. Transm. Infect. 84: 352-355.
26. Lewis, D. A. 2010. The Gonococcus fights back: is this time a knock out? Sex. Transm. Infect. 86:415-421.
27. Lindbäck, E., M. Rahman, S. Jalal, and B. Wretlind. 2002. Mutations in gyrA, gyrB, parC, and parE in quinolone-resistant strains of Neisseria gonorrhoeae. APMIS 110:651-657. (Pubitemid 35335135)
28. Management Sciences for Health in collaboration with World Health Organization. 2009. International drug price indicator guide, 2009 ed. J. Frye (ed.) http://erc.msh.org/dmpguide/pdf/DrugPriceGuide-2009-en.pdf. Accessed 1 February 2011.
29. Matsumoto, T. 2008. Trends of sexually transmitted diseases and antimicrobial resistance in Neisseria gonorrhoeae. Int. J. Antimicrob. Agents 31(Suppl. 1): S35-S39.
30. McKnew, D. L., F. Lynn, J. M. Zenilman, and M. C. Bash. 2003. Porin variation among clinical isolates of Neisseria gonorrhoeae over a 10-year period, as determined by Por variable region typing. J. Infect. Dis. 187:1213-1222.
31. Ministry of Health, Government of Kenya. 2002. Clinical guidelines for diagnosis and treatment of common conditions in Kenya - 2002, 2nd ed. http://collections.infocollections.org/whocountry/en/d/Jh4329e/. Accessed 11 November 2010.
32. Moodley, P., I. M. Martin, K. Pillay, C. A. Ison, and A. W. Sturm. 2006. Molecular epidemiology of recently emergent ciprofloxacin-resistant Neisseria gonorrhoeae in South Africa. Sex. Transm. Dis. 33:357-360.
33. Pandori, M., et al. 2009. Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California. Antimicrob. Agents Chemother. 53:4032-4034.
34. Simonsen, G. S., J. W. Tapsall, B. Allegranzi, E. A. Talbot, and S. Lazzari. 2004. The antimicrobial resistance containment and surveillance approach-a public health tool. Bull. World Health Organ. 82:928-934.
35. Takahata, S., N. Senju, Y. Osaki, T. Yoshida, and T. Ida. 2006. Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 50:3638-3645. (Pubitemid 44684875)
36. Tan, N. J., V. S. Rajan, R. Pang, and E. H. Sng. 1980. Gentamicin in the treatment of infections due to penicillinase-producing gonococci. Br. J. Vener. Dis. 56:394-396.
37. Tapsall, J. 2001. Antimicrobial resistance in Neisseria gonorrhoeae. World Health Organization. http://www.who.int/drugresistance/Antimicrobial- resistance-in-Neisseria-gonorrhoeae.pdf. Accessed 15 December 2008.
38. Tapsall, J. W., et al. 1998. Failure of azithromycin therapy in gonorrhea and discorrelation with laboratory test parameters. Sex. Transm. Dis. 25:505-508.
39. Whiley, D. M., et al. 2010. Alterations of the pilQ gene in Neisseria gonorrhoeae are unlikely contributors to decreased susceptibility to ceftriaxone and cefixime in clinical gonococcal strains. J. Antimicrob. Chemother. 65: 2543-2547.
40. Whiley, D. M., E. A. Limnios, S. Ray, T. P. Sloots, and J. W. Tapsall. 2007. Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone. Antimicrob. Agents Chemother. 51:3111-3116.
41. World Health Organization Western Pacific Programme et al. 2010. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific and South East Asian regions, 2007-2008. Commun. Dis. Intell. 34:1-7.
42. World Health Organization. 2001. Western Pacific Region Gonococcal Antimicrobial Susceptibility Programme (GASP) report - 2000. Commun. Dis. Intell. 25:274-277.
43. World Health Organization. 2001. WHO global strategy for containment of antimicrobial resistance. WHO document WHO/CDS/CSR/DRS/2001.2. World Health Organization, Geneva, Switzerland.
44. Xia, M., Y. Pang, and M. C. Roberts. 1995. Detection of two groups of 25.2 mDa Tet M plasmids by polymerase chain reaction of the downstream region. Mol. Cell. Probes 9:327-332.
45. Yang, Y., et al. 2006. Antimicrobial susceptibility and molecular determinants of quinolone resistance in Neisseria gonorrhoeae isolates from Shanghai. J. Antimicrob. Chemother. 58:868-872.
46. Yong, D., et al. 2004. Epidemiological characteristics and molecular basis of fluoroquinolone-resistant Neisseria gonorrhoeae strains isolated in Korea and nearby countries. J. Antimicrob. Chemother. 54:451-455.
47. Zachariah, R., et al. 2002. Behavioural characteristics, prevalence of Chlamydia trachomatis and antibiotic susceptibility of Neisseria gonorrhoeae in men with urethral discharge in Thyolo, Malawi. Trans. R. Soc. Trop. Med. Hyg. 96:232-235.
48. Zhao, S., et al. 2009. Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob. Agents. Chemother. 53:3744-3751.